Current medical procedures call for dosing patients repeatedly with units of fresh platelets derived from voluntary donors. In contrast, Tacitus Therapeutics’ MEG100 technology is a one-time infusion expected to produce platelets in the patient’s own body naturally. Megakaryocyte cells are eventually cleared by the body (i.e. they don’t engraft permanently like hematopoietic stem cells (HSCs)).
Because platelets typically cannot be cryopreserved, shortages and logistical supply problems arise. However, Tacitus Therapeutics’ technology enables megakaryocytes cryopreservation, long-term storage, and curative potential.